Product Image

Ultimate Neuro Complex

Natural Factors 3 Brains
4.6
★ ★ ★ ★ ★
(360 ratings)
Huperzine 100 mcg
Acetyl L-Carnitine 666 mg
Vinpocetine 10 mg
Ginkgo
Product Image
Score76
A coherent, well-dosed cognitive stack covers several pathways, but it is not a casual-use formula. Bleeding risk, cholinergic effects, and the four-capsule serving require careful fit.
How scoring works
Quantity:120 Capsule(s) • (30 servings)
Goals:
Brain Health
Anti-Aging
Cognitive Support
Productivity Boost
Mental Focus
Metabolism Boost
Energy

Score 76

A coherent, well-dosed cognitive stack covers several pathways, but it is not a casual-use formula. Bleeding risk, cholinergic effects, and the four-capsule serving require careful fit.
How scoring works
$32.96($1.09 per serving)
iHerb
$ 32.96
Report prices

Analysis

The formula combines 666 mg of acetyl-L-carnitine with NAC, alpha-lipoic acid, phosphatidylserine, ginkgo, huperzine A, and vinpocetine. That mix covers mitochondrial support, antioxidant defense, cell membranes, acetylcholine signaling, and cerebral circulation more coherently than a single nootropic.

Huperzine A is clearly supplied at 100 mcg and vinpocetine at 10 mg, while the ginkgo amount is lower and lacks active-marker percentages. Phosphatidylserine is also modest, so not every ingredient carries equal weight.

Four capsules per serving and a fairly high serving cost reduce convenience. The product best suits experienced users who can screen its medication interactions and who want a multi-pathway formula rather than a simple daily supplement.

Who is it for
  • Adults seeking a broad non-stimulant cognitive stack
  • Experienced nootropic users who can review medication fit
  • People interested in acetyl-L-carnitine with cholinergic support
Best for
  • Multi-pathway cognitive support
  • Memory and focus routines
  • Combining mitochondrial and membrane-support ingredients

Pros

  • Provides a useful acetyl-L-carnitine amount
  • Includes NAC and alpha-lipoic acid
  • Clearly states huperzine A and vinpocetine amounts
  • Adds phosphatidylserine and ginkgo
  • Avoids caffeine

Cons

  • Requires four capsules
  • Ginkgo standardization is incomplete
  • Phosphatidylserine is modest
  • The formula has a high interaction burden
  • Serving value is only moderate

Warnings

  • Ginkgo and vinpocetine may compound bleeding risk with anticoagulant or antiplatelet medicines.
  • Huperzine A may add nausea, vivid dreams, slowed heart rate, or other cholinergic effects, especially with cholinergic medication.
  • Vinpocetine is not appropriate during pregnancy or when trying to conceive.
  • Alpha-lipoic acid may lower blood glucose and can require closer monitoring with glucose-lowering medicine.

Nutrient quality

83 Highest impact

Acetyl-L-carnitine hydrochloride and clearly identified botanical extracts are recognizable, well-regarded forms. The main antioxidant and cholinergic ingredients have useful amounts, though phosphatidylserine and ginkgo are comparatively modest.

Ingredient transparency

75 High impact

Specific amounts are provided for every listed active ingredient. Excipients and capsule ingredients are absent from the supplied data.

Customer satisfaction

63 Moderate impact

The supplied aggregate rating indicates favorable satisfaction, though no experience details are provided. No specific feedback is supplied, so recurring complaints cannot be assessed.

Value for money

83 Highest impact

The broad, mostly well-dosed formula supports its premium positioning. Each serving delivers several meaningful actives, making the moderate serving cost defensible.

Report analysis

Goals

Brain Health
Brain Health
Impact
Highest effect
A Goal FitB+ Strength of SupportA CoverageA- Formula Quality
Huperzine · 100 mcg

A broad nootropic stack directly supports memory, attention, brain energy, circulation, and cell-membrane structure. Acetyl-L-carnitine, phosphatidylserine, huperzine A, and vinpocetine provide the clearest brain-health rationale.

Several doses are useful, but ginkgo is below a typical clinical target and its standardization is not shown. Huperzine A can accumulate with frequent use, while ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines.

Study evidence
Acetyl L-Carnitine Supportive 19 studies
Ginkgo Supportive 90 studies
Huperzine Supportive 17 studies
Vinpocetine Supportive 7 studies
Anti-Aging
Anti-Aging
Impact
Highest effect
A- Goal FitB+ Strength of SupportB+ CoverageA Formula Quality

Acetyl-L-carnitine, alpha-lipoic acid, and NAC directly support mitochondrial energy and antioxidant defenses, while phosphatidylserine and selected botanicals target cognitive aging. These ingredients create one of the more focused healthy-aging profiles in the group.

The main actives are disclosed at meaningful amounts, although ginkgo and phosphatidylserine are somewhat modest. Ginkgo and vinpocetine may add bleeding risk for people using anticoagulant or antiplatelet medicines, so clinical review is prudent.

Study evidence
Acetyl L-Carnitine Supportive 1 study
Cognitive Support
Cognitive Support
Impact
Highest effect
A- Goal FitB Strength of SupportA- CoverageA- Formula Quality
Huperzine · 100 mcgAcetyl L-Carnitine · 666 mg

Acetyl-L-carnitine, huperzine A, phosphatidylserine, ginkgo, vinpocetine, and antioxidant compounds directly target several cognitive mechanisms. The formula addresses acetylcholine, cellular energy, membrane structure, circulation, and oxidative stress.

Acetyl-L-carnitine and huperzine A are meaningfully dosed, while ginkgo and phosphatidylserine are moderate. Huperzine A has a long action and may accumulate with daily use, while ginkgo can increase bleeding risk with anticoagulant or antiplatelet medicines.

Study evidence
Acetyl L-Carnitine Supportive 20 studies
Ginkgo Supportive 87 studies
Huperzine Supportive 22 studies
Productivity Boost
Productivity Boost
Impact
Highest effect
B+ Goal FitA- Strength of SupportB+ CoverageA- Formula Quality
Acetyl L-Carnitine · 666 mgAcetyl L-Carnitine · 666 mgVinpocetine · 10 mgHuperzine · 100 mcg

The formula directly targets cognitive performance through acetyl-L-carnitine, huperzine A, phosphatidylserine, ginkgo, and vinpocetine. Several ingredients reach useful amounts, although ginkgo standardization and phosphatidylserine depth are weaker.

The compact stack is more goal-focused than a general multivitamin. Ginkgo may raise bleeding risk with anticoagulant or antiplatelet medicines, and huperzine A lacks cycling guidance despite its potential to accumulate.

Study evidence
Acetyl L-Carnitine Supportive 1 study
Acetyl L-Carnitine Supportive 1 study
Ginkgo Supportive 20 studies
Ginkgo Supportive 12 studies
Huperzine No effect 1 study
Mental Focus
Mental Focus
Impact
Highest effect
B+ Goal FitB+ Strength of SupportB CoverageA- Formula Quality
Acetyl L-Carnitine · 666 mgHuperzine · 100 mcg

Acetyl-L-carnitine, phosphatidylserine, huperzine A, vinpocetine, and ginkgo create a clearly targeted cognitive formula. Useful acetyl-L-carnitine and huperzine amounts support cellular energy and cholinergic signaling, while ginkgo and phosphatidylserine fall below common full study doses.

Exact amounts and complementary mechanisms make the formula more coherent than a typical broad multivitamin. Ginkgo may increase bleeding risk with anticoagulant or antiplatelet medicines, while huperzine’s long action makes continuous daily use without cycling guidance a concern.

Study evidence
Acetyl L-Carnitine Supportive 7 studies
Ginkgo Supportive 28 studies
Huperzine Not classified

No linked studies yet.

Vinpocetine Supportive 3 studies
Metabolism Boost
Metabolism Boost
Impact
High effect
B Goal FitB+ Strength of SupportC+ CoverageA Formula Quality
Acetyl L-Carnitine · 666 mg

Acetyl-L-carnitine and alpha lipoic acid form a focused mitochondrial support combination. Their disclosed amounts are substantial, and the acetylated carnitine form is well suited to cellular energy support.

The formula does not cover thermogenesis, thyroid nutrition, or glycemic control. Evidence also supports mitochondrial function more clearly than a reliable increase in metabolic rate or body-fat loss.

Study evidence
Acetyl L-Carnitine Adverse 1 study

Ingredients

IngredientAmount per serving
Acetyl-L-Carnitine (Acetyl-L-Carnitine HCl)
 666 mg
N-Acetyl-L-Cysteine
400 mg
Alpha Lipoic Acid
200 mg
Ginkgo extract (Ginkgo biloba)
 80 mg
Phosphatidylserine (Helianthus annuus)
 66 mg
Vinpocetine
10 mg
Huperzia serrata extract
10 mg
Huperzine A
100 mcg
Gluten Free Adults 18–50 Dairy Free Sugar Free Vegetarian
Report overview
Huperzine · 100 mcg OverallScore89
A+ Active Ingredient Quality & BioavailabilityA- Dose, Safety & Label TransparencyB- Value

Huperzine A is clearly tied to Huperzia serrata extract and supplied at a well-targeted 100 mcg amount. Capsule delivery supports precise dosing, but no cycling guidance addresses its long half-life and potential accumulation. The cost per active amount is high, although substantial acetyl-L-carnitine, N-acetyl-L-cysteine, alpha-lipoic acid, and phosphatidylserine provide meaningful nootropic value.

View ingredientView products
Acetyl L-Carnitine (Acetyl-L-Carnitine HCl) · 666 mg OverallScore83
A- Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyD- Value

Acetyl-L-carnitine HCl provides 666 mg, placing the clearly labeled dose in a useful daily range. Alpha-lipoic acid and phosphatidylserine broaden the cognitive formula, though no manufacturing purity claim is supplied. The four-capsule serving and only moderate dose-specific value are the main trade-offs.

View ingredientView products
Vinpocetine · 10 mg OverallScore81
A Active Ingredient Quality & BioavailabilityA- Dose, Safety & Label TransparencyD+ Value

Vinpocetine is clearly identified with an exact 10 mg amount in the standard target range. 4 capsules are needed for a low-volume compound, reducing serving convenience. The supplied data does not fully show inactive ingredients, so excipient quality remains partly uncertain. Vinpocetine alone is costly, but substantial acetyl-L-carnitine, alpha-lipoic acid, ginkgo, and phosphatidylserine partly offset the premium.

View ingredientView products
Loading alternative details
75 Performance

Memoractiv

Thorne
<p>For a stronger fit within the relevant ingredient pathway, branded ashwagandha, ginkgo phytosome, carotenoids, caffeine, and acetyl-L-carnitine create a well-specified cognitive and stress-support formula. It does not replace vinpocetine and huperzine A; several supporting doses are modest and the serving cost is high, but ingredient quality and strong aggregate satisfaction support its premium position.</p>
75 Performance

Brain Cell Support

Metabolic Maintenance
<p>For a stronger fit within the relevant ingredient pathway, a focused cognitive formula pairs acetyl-L-carnitine, citicoline, phosphatidylserine, ginkgo, and gotu kola in generally useful amounts. It does not replace vinpocetine and huperzine A; strong aggregate satisfaction supports confidence, but the high serving cost and ambiguous repeated extract entries temper its appeal.</p>
76 Performance

Nu Clarity

CogniTune Smarter Health
<p>For a stronger fit within the relevant ingredient pathway, bacopa, alpha-GPC, phosphatidylserine, ginkgo, rhodiola, and huperzine A form a coherent cognitive blend at generally useful levels. It does not replace vinpocetine; some duplicated standardization entries cloud the true extract amounts, and huperzine A may be unsuitable with cholinergic medicines.</p>
79 Budget

Ginkgo with Vinpocetine

Swanson Superior Herbs
<p>At a lower serving cost than the original, ginkgo and vinpocetine form a concise circulation-focused cognitive blend at practical amounts. It does not replace acetyl-L-carnitine and huperzine A; missing ginkgo standardization limits confidence in extract quality.</p>
65 Budget

SharpMind

Solaray
<p>At a lower serving cost than the original, the broad cognitive stack includes several relevant pathways but relies on many modest amounts. It does not replace acetyl-L-carnitine and vinpocetine; weak standardization and multiple neuroactive ingredients make its potency and suitability difficult to judge.</p>
70 Budget

Brain Regain

Protocol For Life Balance
<p>At a lower serving cost than the original, ginkgo, huperzine, rosemary, and gotu kola form a coherent cognitive-support blend. It does not replace acetyl-L-carnitine and vinpocetine; most core nutrients are modestly dosed, and full safety and usage details are not supplied.</p>
82 Value

Herbal Extract Memory Complex

Swanson Ultra
<p>For a more favorable quality-to-cost balance, the compact blend covers circulation and cholinergic pathways with useful ginkgo and vinpocetine amounts. It does not replace acetyl-L-carnitine and phosphatidylserine; unstated ginkgo standardization and huperzine yield leave important potency uncertainty.</p>
76 Value

Brain Elevate

NOW
<p>For a more favorable quality-to-cost balance, ginkgo, huperzine, rosemary, and gotu kola form a coherent cognitive-support blend. It does not replace acetyl-L-carnitine and vinpocetine; several core nutrients are modestly dosed, but the long supply and focused formula support good value.</p>
72 Value

NeuroIGNITE

Havasu Nutrition
<p>For a more favorable quality-to-cost balance, bacopa is the clearest strength, while several other cognitive ingredients are included at light amounts. It does not replace vinpocetine; St. John’s wort can interact with antidepressants, hormonal contraceptives, anticoagulants, and many other medicines, making this formula unsuitable for unsupervised use alongside those drugs.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review.
    von Gunten A; Schlaefke S; Überla K · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2017
    Meta-analysis1,628 participants4 studies pooledCognitive Support Brain Health forGinkgo
  2. Ginkgo biloba for cognitive impairment and dementia.
    Wieland LS; Ludeman E; Chi Y; Feinberg TM; Chen IH; Chen KH; Zhu Y; Wolverson E; Amri H · The Cochrane database of systematic reviews · 2026
    Meta-analysis10,613 participants82 studies pooledCognitive Support forGinkgo
  3. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.
    Malaguarnera M; Gargante MP; Cristaldi E; Vacante M; Risino C; Cammalleri L; Pennisi G; Rampello L · Digestive diseases and sciences · 2008
    Randomized trial125 participantsCognitive Support Brain Health forAcetyl L-Carnitine
  4. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
    Thal LJ; Calvani M; Amato A; Carta A · Neurology · 2000
    Randomized trial229 participantsCognitive Support forAcetyl L-Carnitine
  5. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis.
    Zheng W; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Sun F; D'Arcy C; Meng X; Xiang YT · Human psychopharmacology · 2017
    Meta-analysis1,117 participants12 studies pooledCognitive Support forHuperzine
  6. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
    Rafii MS; Walsh S; Little JT; Behan K; Reynolds B; Ward C; Jin S; Thomas R; Aisen PS; Alzheimer's Disease Cooperative Study · Neurology · 2011
    Randomized trial210 participantsCognitive Support forHuperzine
  7. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial.
    Malaguarnera G; Catania VE; Bertino G; Chisari LM; Castorina M; Bonfiglio C; Cauli O; Malaguarnera M · Current pharmaceutical design · 2022
    Randomized trial92 participantsAnti-Aging forAcetyl L-Carnitine
  8. Long-term acetyl-L-carnitine treatment in Alzheimer's disease.
    Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M · Neurology · 1991
    Randomized trial130 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  9. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome.
    Herrmann WM; Dietrich B; Hiersemenzel R · International journal of clinical pharmacology research · 1990
    Randomized trialBrain Health forAcetyl L-Carnitine
  10. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.
    Malaguarnera M; Vacante M; Motta M; Giordano M; Malaguarnera G; Bella R; Nunnari G; Rampello L; Pennisi G · Metabolic brain disease · 2012
    Randomized trial61 participantsBrain Health Cognitive Support forAcetyl L-Carnitine
  11. Acetyl-L-carnitine in the treatment of mildly demented elderly patients.
    Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U · International journal of clinical pharmacology research · 1990
    Randomized trial60 participantsBrain Health Mental Focus forAcetyl L-Carnitine
  12. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis.
    Tan MS; Yu JT; Tan CC; Wang HF; Meng XF; Wang C; Jiang T; Zhu XC; Tan L · Journal of Alzheimer's disease : JAD · 2015
    Meta-analysis2,561 participants9 studies pooledBrain Health forGinkgo
  13. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.
    Riepe M; Hoerr R; Schlaefke S · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2025
    Meta-analysis782 participants4 studies pooledBrain Health Productivity Boost forGinkgo
  14. Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial.
    Cui M; You T; Zhao Y; Liu R; Guan Y; Liu J; Liu X; Wang X; Dong Q · Frontiers in pharmacology · 2023
    Randomized trial201 participantsBrain Health Productivity Boost forGinkgo
  15. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg.
    Herrschaft H; Nacu A; Likhachev S; Sholomov I; Hoerr R; Schlaefke S · Journal of psychiatric research · 2012
    Randomized trial410 participantsBrain Health forGinkgo
  16. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis.
    Xing SH; Zhu CX; Zhang R; An L · Evidence-based complementary and alternative medicine : eCAM · 2014
    Meta-analysis825 participants10 studies pooledBrain Health Cognitive Support forHuperzine
  17. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
    Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G · Zhonghua yi xue za zhi · 2002
    Randomized trial202 participantsBrain Health Cognitive Support forHuperzine
  18. Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial.
    Zhang Z; Shen Y; Li J; Tang Y; Zhou P; Ying T; Mo R; Ru Z; Zhao G; Zhu J; Li S; Zhao H · International journal of surgery (London, England) · 2026
    Randomized trial123 participantsBrain Health Cognitive Support forHuperzine
  19. Treatment with Huperzine A improves cognition in vascular dementia patients.
    Xu ZQ; Liang XM; Juan-Wu; Zhang YF; Zhu CX; Jiang XJ · Cell biochemistry and biophysics · 2012
    Randomized trial78 participantsBrain Health forHuperzine
  20. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.
    Gul A; Bakht J; Mehmood F · Journal of the Chinese Medical Association : JCMA · 2019
    Randomized trial100 participantsBrain Health forHuperzine
  21. Combination of Vinpocetine and Dexamethasone Alleviates Cognitive Impairment in Nasopharyngeal Carcinoma Patients following Radiation Injury.
    Zhang P; Cao Y; Chen S; Shao L · Pharmacology · 2021
    Randomized trial60 participantsBrain Health forVinpocetine
  22. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study.
    Szilágyi G; Nagy Z; Balkay L; Boros I; Emri M; Lehel S; Márián T; Molnár T; Szakáll S; Trón L; Bereczki D; Csiba L; Fekete I; Kerényi L; Galuska L; Varga J; Bönöczk P; Vas A; Gulyás B · Journal of the neurological sciences · 2005
    Randomized trial13 participantsBrain Health forVinpocetine
  23. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine.
    Bönöczk P; Gulyás B; Adam-Vizi V; Nemes A; Kárpáti E; Kiss B; Kapás M; Szántay C; Koncz I; Zelles T; Vas A · Brain research bulletin · 2001
    Narrative reviewBrain Health forVinpocetine
  24. Effect of vinpocetine (cognitol™) on cognitive performances of a nigerian population.
    Ogunrin A · Annals of medical and health sciences research · 2014
    Non-randomized trial112 participantsBrain Health Mental Focus forVinpocetine
  25. [Study of the effects of vinpocetin on cognitive functions].
    Valikovics A; Csányi A; Németh L · Ideggyogyaszati szemle · 2012
    Clinical trialBrain Health forVinpocetine
  26. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
    Torrioli MG; Vernacotola S; Peruzzi L; Tabolacci E; Mila M; Militerni R; Musumeci S; Ramos FJ; Frontera M; Sorge G; Marzullo E; Romeo G; Vallee L; Veneselli E; Cocchi E; Garbarino E; Moscato U; Chiurazzi P; D'Iddio S; Calvani M; Neri G · American journal of medical genetics. Part A · 2008
    Randomized trial63 participantsCognitive Support forAcetyl L-Carnitine
  27. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.
    Malaguarnera M; Gargante MP; Cristaldi E; Colonna V; Messano M; Koverech A; Neri S; Vacante M; Cammalleri L; Motta M · Archives of gerontology and geriatrics · 2008
    Randomized trial96 participantsCognitive Support forAcetyl L-Carnitine
  28. Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.
    Tian X; Xu Q; Xia X; Zhang Y; Meng X; Wang A · Journal of neurology · 2024
    Randomized trial3,163 participantsCognitive Support forGinkgo
  29. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
    Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF · JAMA · 1997
    Randomized trial309 participantsCognitive Support Productivity Boost forGinkgo
  30. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial.
    Bachinskaya N; Hoerr R; Ihl R · Neuropsychiatric disease and treatment · 2011
    Randomized trial410 participantsCognitive Support forGinkgo
  31. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial.
    Ihl R; Bachinskaya N; Korczyn AD; Vakhapova V; Tribanek M; Hoerr R; Napryeyenko O; GOTADAY Study Group · International journal of geriatric psychiatry · 2013
    Randomized trial410 participantsCognitive Support forGinkgo
  32. [Drug evaluation of huperzine A in the treatment of senile memory disorders].
    Zhang RW; Tang XC; Han YY; Sang GW; Zhang YD; Ma YX; Zhang CL; Yang RM · Zhongguo yao li xue bao = Acta pharmacologica Sinica · 1992
    Randomized trial56 participantsCognitive Support forHuperzine
  33. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
    Malaguarnera M; Vacante M; Giordano M; Pennisi G; Bella R; Rampello L; Malaguarnera M; Li Volti G; Galvano F · The American journal of clinical nutrition · 2011
    Randomized trial121 participantsEnergy forAcetyl L-Carnitine
  34. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin.
    Malaguarnera M; Vacante M; Bertino G; Neri S; Malaguarnera M; Gargante MP; Motta M; Lupo L; Chisari G; Bruno CM; Pennisi G; Bella R · Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2012
    Randomized trial60 participantsEnergy forAcetyl L-Carnitine
  35. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy.
    Malaguarnera M; Bella R; Vacante M; Giordano M; Malaguarnera G; Gargante MP; Motta M; Mistretta A; Rampello L; Pennisi G · Scandinavian journal of gastroenterology · 2011
    Randomized trial67 participantsEnergy forAcetyl L-Carnitine
  36. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.
    Sun Y; Shu Y; Liu B; Liu P; Wu C; Zheng R; Zhang X; Zhuang Z; Deng Y; Zheng L; Xu Q; Jiang B; Ouyang X; Gao J; Xu N; Li X; Jiang S; Liang C; Yao Y · Experimental and therapeutic medicine · 2020
    Randomized trial239 participantsEnergy forAcetyl L-Carnitine
  37. Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review.
    Kumar R; Nuñez NA; Joshi N; Joseph B; Verde A; Seshadri A; Cuellar Barboza AB; Prokop LJ; Medeiros GC; Singh B · Bipolar disorders · 2024
    Systematic reviewEnergy forAcetyl L-Carnitine
  38. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.
    Malaguarnera G; Pennisi M; Gagliano C; Vacante M; Malaguarnera M; Salomone S; Drago F; Bertino G; Caraci F; Nunnari G; Malaguarnera M · Hepatitis monthly · 2014
    Randomized trial62 participantsMental Focus Productivity Boost forAcetyl L-Carnitine
  39. [Psycho-functional changes in attention and learning under the action of L-acetylcarnitine in 17 young subjects. A pilot study of its use in mental deterioration].
    Lino A; Boccia MM; Rusconi AC; Bellomonte L; Cocuroccia B · La Clinica terapeutica · 1992
    Non-randomized trial17 participantsMental Focus forAcetyl L-Carnitine
  40. Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial.
    Arnold LE; Amato A; Bozzolo H; Hollway J; Cook A; Ramadan Y; Crowl L; Zhang D; Thompson S; Testa G; Kliewer V; Wigal T; McBurnett K; Manos M · Journal of child and adolescent psychopharmacology · 2008
    Randomized trial112 participantsMental Focus forAcetyl L-Carnitine
  41. Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Martí-Carvajal AJ; Gluud C; Arevalo-Rodriguez I; Martí-Amarista CE · The Cochrane database of systematic reviews · 2019
    Meta-analysis398 participants5 studies pooledMental Focus forAcetyl L-Carnitine
  42. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review.
    Hort J; Duning T; Hoerr R · Neuropsychiatric disease and treatment · 2023
    Systematic review946 participants9 studies pooledMental Focus forGinkgo
  43. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Phytomedicine : international journal of phytotherapy and phytopharmacology · 2012
    Randomized trial216 participantsMental Focus forGinkgo
  44. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
    Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R · Pharmacopsychiatry · 1996
    Randomized trial216 participantsMental Focus forGinkgo
  45. Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial.
    Li S; Zhang X; Fang Q; Zhou J; Zhang M; Wang H; Chen Y; Xu B; Wu Y; Qian L; Xu Y · Stroke and vascular neurology · 2021
    Randomized trial348 participantsMental Focus forGinkgo
  46. Ginkgo biloba in the Aging Process: A Narrative Review.
    Barbalho SM; Direito R; Laurindo LF; Marton LT; Guiguer EL; Goulart RA; Tofano RJ; Carvalho ACA; Flato UAP; Capelluppi Tofano VA; Detregiachi CRP; Bueno PCS; Girio RSJ; Araújo AC · Antioxidants (Basel, Switzerland) · 2024
    Narrative review14 studies pooledMental Focus forGinkgo
  47. "Brain-specific" nutrients: a memory cure?
    McDaniel MA; Maier SF; Einstein GO · Nutrition (Burbank, Los Angeles County, Calif.) · 2004
    Narrative reviewMental Focus forVinpocetine
  48. Psychopharmacological effects of vinpocetine in normal healthy volunteers.
    Subhan Z; Hindmarch I · European journal of clinical pharmacology · 1985
    Randomized trial12 participantsMental Focus forVinpocetine
  49. Low Bioavailability and High TMAO Production: Novel Insights Into Acetylcarnitine and Carnitine Metabolism.
    Krims-Davis K; Ozola M; Razzivina V; Gukalova B; Konrade I; Dambrova M; Liepinsh E · Molecular nutrition & food research · 2025
    Randomized trialMetabolism Boost forAcetyl L-Carnitine
  50. [Ginkgo biloba extract EGb 761 in the treatment of dementia: evidence of efficacy and tolerability].
    Kasper S; Schubert H · Fortschritte der Neurologie-Psychiatrie · 2009
    Meta-analysis10 studies pooledProductivity Boost forGinkgo
  51. Dietary Flavonoids and Human Cognition: A Meta-Analysis.
    Cheng N; Bell L; Lamport DJ; Williams CM · Molecular nutrition & food research · 2022
    Meta-analysis5,519 participants80 studies pooledProductivity Boost forGinkgo
  52. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba.
    Elsabagh S; Hartley DE; File SE · Journal of psychopharmacology (Oxford, England) · 2005
    Randomized trial87 participantsProductivity Boost forGinkgo
  53. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial.
    Gavrilova SI; Preuss UW; Wong JW; Hoerr R; Kaschel R; Bachinskaya N; GIMCIPlus Study Group · International journal of geriatric psychiatry · 2015
    Randomized trial160 participantsProductivity Boost forGinkgo
  54. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers.
    Kennedy DO; Jackson PA; Haskell CF; Scholey AB · Human psychopharmacology · 2008
    Randomized trial78 participantsProductivity Boost forGinkgo
  55. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial.
    Wessinger CM; Inman CL; Weinstock J; Weiss EP · International journal of exercise science · 2025
    Randomized trial15 participantsProductivity Boost forHuperzine
  56. Effect of Ginkgo biloba extracts in the prevention of posterior capsule opacification after cataract surgery: A randomized clinical trial.
    Amiri AA; Jafari R; Amiri AA; Rad HA; Daneshvar F; Charati JY; Amiri AA · Oman journal of ophthalmology · 2025
    Randomized trial144 participantsVision Support forGinkgo
  57. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma.
    Quaranta L; Bettelli S; Uva MG; Semeraro F; Turano R; Gandolfo E · Ophthalmology · 2003
    Randomized trial27 participantsVision Support forGinkgo
  58. [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration].
    Fies P; Dienel A · Wiener medizinische Wochenschrift (1946) · 2002
    Randomized trial99 participantsVision Support forGinkgo
  59. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma.
    Park JW; Kwon HJ; Chung WS; Kim CY; Seong GJ · Korean journal of ophthalmology : KJO · 2012
    Randomized trial30 participantsVision Support forGinkgo
  60. [The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. A preliminary double-blind versus placebo study].
    Lanthony P; Cosson JP · Journal francais d'ophtalmologie · 1989
    Randomized trial29 participantsVision Support forGinkgo
  61. [Effect of vasoactive agents on visual functions and ocular blood flow in patients with early manifestations of age-related macular degeneration].
    Avetisov SE; Kiseleva TN; Lagutina IuM; Kravchuk EA · Vestnik oftalmologii · 2007
    Non-randomized trial40 participantsVision Support forVinpocetine